-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$55.75181.85% Upside
Neurogene Inc. Frequently Asked Questions
-
What analysts cover Neurogene Inc.?
Neurogene Inc. has been rated by research analysts at BMO Capital, Stifel Nicolaus, H.C. Wainwright, Robert W. Baird in the past 90 days.